Related Experiment Video

Updated: Aug 14, 2026

Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock
16:31

Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock

Published on: June 6, 2011

Pharmacologic problems in shock research

H R Adams

    Advances in Shock Research
    |January 1, 1983
    PubMed

    More Related Videos

    Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

    Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

    Published on: June 12, 2021

    Developing a Clinically Relevant Hemorrhagic Shock Model in Rats08:14

    Developing a Clinically Relevant Hemorrhagic Shock Model in Rats

    Published on: March 22, 2024

    Related Concept Videos

    Adrenergic Agonists: Therapeutic Uses01:30

    Adrenergic Agonists: Therapeutic Uses

    Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
    Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
    Allergies and anaphylaxis:...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Blood Pressure Imbalances and Circulatory Shock01:24

    Blood Pressure Imbalances and Circulatory Shock

    Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
    Blood Pressure: Hypertension and Hypotension
    Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
    Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

    Pharmacokinetic–Pharmacodynamic Relationship: Problems

    The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...